Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: Design, development and place in therapy

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.

Original languageEnglish (US)
Pages (from-to)4047-4060
Number of pages14
JournalDrug Design, Development and Therapy
Volume10
DOIs
StatePublished - Dec 14 2016

Fingerprint

Adrenal Cortex Hormones
Asthma
Nebulizers and Vaporizers
Dry Powder Inhalers
Chronic Obstructive Pulmonary Disease
Therapeutics
Secondary Prevention
vilanterol
fluticasone furoate
Clinical Trials
Guidelines
Safety

Keywords

  • Asthma
  • Combined inhaler
  • Dry powder inhaler
  • Fluticasone furoate/vilanterol trifenatate
  • Inhaled corticosteroid
  • Long-acting beta agonist
  • Persistent asthma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{484640f9a97c42faa68aa116f845c138,
title = "Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: Design, development and place in therapy",
abstract = "The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.",
keywords = "Asthma, Combined inhaler, Dry powder inhaler, Fluticasone furoate/vilanterol trifenatate, Inhaled corticosteroid, Long-acting beta agonist, Persistent asthma",
author = "Albertson, {Timothy E} and Bullick, {Samuel W.} and Michael Schivo and Sutter, {Mark E}",
year = "2016",
month = "12",
day = "14",
doi = "10.2147/DDDT.S113573",
language = "English (US)",
volume = "10",
pages = "4047--4060",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma

T2 - Design, development and place in therapy

AU - Albertson, Timothy E

AU - Bullick, Samuel W.

AU - Schivo, Michael

AU - Sutter, Mark E

PY - 2016/12/14

Y1 - 2016/12/14

N2 - The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.

AB - The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.

KW - Asthma

KW - Combined inhaler

KW - Dry powder inhaler

KW - Fluticasone furoate/vilanterol trifenatate

KW - Inhaled corticosteroid

KW - Long-acting beta agonist

KW - Persistent asthma

UR - http://www.scopus.com/inward/record.url?scp=85007483139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007483139&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S113573

DO - 10.2147/DDDT.S113573

M3 - Review article

C2 - 28008228

AN - SCOPUS:85007483139

VL - 10

SP - 4047

EP - 4060

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -